Rapid increase in the usage of microfluidics for the purpose of diagnostics and drug delivery is likely to drive its production sales in the coming years. Rising discretionary funding from the national labs for the purpose of research and development, especially in the developed countries is anticipated to be a major factor contributing towards the growth of microfluidics market. Apart from this, wide-ranging availability of feasible microfluidic devices and improving healthcare infrastructure are also expected to boost the revenue growth of microfluidics market.
A research firm carried out a major study on the microfluidics market’s report and the related analysts delivered facts as well as figures based on the detailed analysis regarding the microfluidics market across the world. Therefore, report on the microfluidics market illustrates that the global market is likely to develop at an outstanding 14.4% CAGR over the assessment period, 2016-2026, for surpassing a value of approximately US$ 11Bn by 2026-end.
The major companies that are operating in the microfluidics market are F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Abbott Laboratories, Qiagen NV, Agilent Technologies, Fluidigm Corporation and Thermo Fisher Scientific Inc. Manufacturers and the major companies are working on initiating strategies, which is inclusive of increasing product portfolio as well as innovation of the developing and existing products, which exclusively would be favorable for end-users.
Fluidigm Corporation Introduces Scalable & Efficient Library Prep Workflow
The major companies along with manufacturers must take account of the point that Fluidigm Corporation has been making strategic developments for the expansion of their business as well as customer base across the globe. Fluidigm Corporation has recently introduced Advanta™ CFTR NGS Library Prep Assay, which is highly scalable and efficient NGS (next-generation sequencing) library prep workflow. This development took place as a result of sequencing cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Next-generation sequencing has been offering a more wide-ranging method to the cystic fibrosis transmembrane conductance regulator genetic analysis, compared to traditional genotyping methods. The notable point for the customers is that the present next-generation sequencing aimed sequencing library prep plans but, these can turn out to be significantly expensive as well as labor-intensive with regards to molecular laboratory.
Insights on Development of Advanta™ CFTR NGS Library Prep Assay
The major companies along with manufacturers must take account of the point that Advanta™ CFTR NGS Library Prep Assay is mainly developed for research purposes along with Juno™ system. This new development is said to be automating the aimed enrichment of the cystic fibrosis transmembrane conductance regulator alternatives from every 27 exons of the gene as well as chosen intronic regions by means of proven microfluidics technology.
Fluidigm Corporation is taking immense efforts to provide significant opportunity of savings in the cost per sample, sustainability of the workflow helps in reducing the hands-on-time and most of all, preserves precious reagents by decreasing responses to nanoliter scale. The most important point is that this new product development is considered as a representative of the increasing array of the highly-important genetic assays and the development is for utilizing it with the automated microfluidic systems of Fluidigm Corporation.
A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-398